Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2026

Conditions

Myasthenia Gravis

Interventions

DRUG

CD19-BCMA Targeted CAR-T Dose 1

5.0 e5/ kg CD19-BCMA CAR-T positive T cells

DRUG

CD19-BCMA Targeted CAR-T Dose 2

1.5 e6/ kg CD19-BCMA CAR-T positive T cells

DRUG

CD19-BCMA Targeted CAR-T Dose 2

5 e6/ kg CD19-BCMA CAR-T positive T cells

Trial Locations (1)

RECRUITING

Tangdu Hospital, The Fourth Military Medical University, Xi'an

All Listed Sponsors

lead

Ting Chang, MD

OTHER